Search clinical trials for: MK0859

Total 121 results

Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Asthma
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Terminated

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

Relapsing-Remitting Multiple Sclerosis
Merck Sharp & Dohme LLC

Terminated

A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Osteoarthritis

United States, Chile, Colombia, Mexico, Poland
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Completed

MK0457 in Patients With Leukemia (0457-003)

Myelodysplastic Syndromes | Myelogenous Leukemia, Chronic | Chronic Myelogenous Leukemia in Blast Crisis | Lymphocytic Leukemia, B Cell, Acute
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Terminated

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Ambulatory Blood Pressure
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Odanacatib (0822-059)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Prostatic Neoplasms
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)

Coronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Merck Sharp & Dohme LLC

Terminated

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Colorectal Cancer | Advanced Solid Tumors
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Urinary Tract Infection
Merck Sharp & Dohme LLC

Completed

Pediatric Expanded Access Program-Oral Solution (0831-908)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

Urinary Tract Infection
Merck Sharp & Dohme LLC

Terminated

Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

Urinary Tract Infections
Merck Sharp & Dohme LLC

Completed

To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

Sepsis
Merck Sharp & Dohme LLC

Completed

To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

Pneumonia | Urinary Tract Infection | Infection
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Major Depressive Disorder
Main Line Health

Completed

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

Brain Metastasis

United States

3

Subscribe